Physician profile
William Herron
NPI 1962685958
$4,211.30
in general payments reported to CMS, 2019-2025
32 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $648 · 2021: $1,229 · 2022: $658 · 2023: $451 · 2024: $319 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,130.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $703.33 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $303.17 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.56 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $255.22 | 2019-2024 | |
| Lilly USA, LLC | $222.58 | 2020-2022 | |
| Glaxosmithkline, LLC. | $185.08 | 2019-2025 | Trelegy Ellipta |
| Abbott Laboratories | $171.43 | 2021-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $167.07 | 2019-2021 | |
| Allergan, INC. | $165.57 | 2019-2020 | |
| Amarin Pharma, INC. | $122.16 | 2019-2022 | |
| Corcept Therapeutics | $52.73 | 2021 | |
| Exact Sciences Corporation | $46.02 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $44.10 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.50 | 2019-2024 | Airsupra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $36.03 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $34.01 | 2025 | Gemtesa |
| Jazz Pharmaceuticals INC. | $32.86 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.47 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.67 | 2024 | Gvoke Hypopen |
| Mylan Specialty L.P. | $20.26 | 2020 | |
| Acadia Pharmaceuticals INC | $18.25 | 2025 | Daybue |
| Idorsia Pharmaceuticals US INC | $16.80 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $15.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.71 | 2019 | |
| Eisai INC. | $13.49 | 2020 | |
| Vanda Pharmaceuticals INC. | $13.24 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.00 | 2021 | |
| Genentech USA, INC. | $11.69 | 2019 | |
| Medtronic USA, INC. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Herron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.